Covid vaccine maker Oxford Biomedica signs new three-year deal with AstraZeneca | Business

One of the key British manufacturers behind the Oxford University-AstraZeneca Covid-19 vaccine has signed a new three-year agreement with the drugs company.

Oxford Biomedica, whose manufacturing commitments under a previous deal for AstraZeneca’s vaccine end in the final quarter of this year, said that the new deal should “facilitate potential future manufacturing opportunities” for the vaccine.

The company also said that it expected to record about £30 million in revenue from the existing agreement with AstraZeneca during this financial year, higher than City forecasts.

The active ingredient of the vaccine is being made at Oxford Biomedica’s £20 million, 84,000 sq ft facility called OxBox on the site of a former Royal Mail sorting office on the city’s business park. The company, a specialist contract